Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 4, 2013, Pages 879-887

  Zucchetti, Massimo ^a   Bonezzi, Katiuscia ^a   Frapolli, Roberta ^a   Sala, Federica ^a   Borsotti, Patrizia ^a   Zangarini, Monique ^a   Cvitkovic, Esteban ^b   Noel, Kay ^b   Ubezio, Paolo ^a   Giavazzi, Raffaella ^a   D'Incalci, Maurizio ^a   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Oncoethix SA   (Switzerland)

Author keywords

Combination therapy; Galectin 1; Inhibitors of angiogenesis; OTX008; Pharmacokinetics; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; GALECTIN 1; OTX 008; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CALIXARENES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENDOTHELIAL CELLS; FEMALE; GALECTIN 1; GLIOBLASTOMA; HALF-LIFE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PYRROLES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885386587     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2270-2     Document Type: Article

References (24)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
2. Bridges EM, Harris AL (2011) The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 81:1183-1191
3. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
4. Taraboletti G, Rusnati M, Ragona L, Colombo G (2010) Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1:662-673
5. Belotti D, Foglieni C, Resovi A, Giavazzi R, Taraboletti G (2011) Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol 43:1674-1685
6. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354:233-242
7. Dings RP, Arroyo MM, Lockwood NA, van Eijk LI, Haseman JR, Griffioen AW, Mayo KH (2003) Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J 373:281-288
8. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW (2002) The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 16:1991-1993
9. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395-3402
10. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-15980
11. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29-41
12. Thijssen VL, Poirier F, Baum LG, Griffioen AW (2007) Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110:2819-2827
13. Rabinovich GA (2005) Galectin-1 as a potential cancer target. Br J Cancer 92:1188-1192
14. Rezai K, Durand S, Lachaux N, Raymond E, Herait P, Lokiec F et al (2013) OTX008 pharmacokinetics (PK) during the first-in-man phase I study in patients with advanced solid tumors. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10, Washington, DC. Philadelphia (PA), AACR. Abstract nr 33
15. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH (2006) Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst 98:932-936
16. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH (2012) Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55:5121-5129
17. Dings RPM, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH (2013) Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs. doi: 10.1007/s10637-013-9932-0
18. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745
19. Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R (2005) Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin Cancer Res 11:2720-2726
20. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12:1839-1849
21. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D'Incalci M, Ribatti D, Giavazzi R (2004) Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 90:2418-2424
22. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G (2006) Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42:2821-2832
23. Hsieh SH, Ying NW, Wu MH, Chiang WF, Hsu CL, Wong TY, Jin YT, Hong TM, Chen YL (2008) Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27:3746-3753
24. Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, Leffler H (2011) The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem 286:13801-13804